152
Participants
Start Date
March 16, 2020
Primary Completion Date
April 30, 2024
Study Completion Date
March 30, 2025
PD-1 blocking antibody
"1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
Gemcitabine
Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Cisplatin
Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Intensity-modulated radiotherapy
Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Fujian Provinve Cancer Hospital, Fuzhou
Cancer Hospital of Guizhou Medical University, Guiyang
Hubei Province Cancer Hosiptal, Wuhan
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Xiangya Hospital Central South University, Changsha
Zhejiang Province Cancer Hospital, Hangzhou
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Sun Yat-sen University
OTHER